{"analyses":[{"ciLowerLimit":"0.56","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.93","estimateComment":"Stratified Cox model with Efron's tie handling method with treatment as a covariate stratified by Stage (II versus III), TPS (\\>=50% versus \\<50%), Histology (Squamous versus Non-squamous) and Region (East-Asia versus non-East Asia).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.00517","pValueComment":"One-sided p-value based on log-rank test stratified by Stage (II versus III), TPS (\\>=50% versus \\<50%), Histology (Squamous versus Non-squamous) and Region (East-Asia versus non-East Asia).","paramType":"Hazard Ratio (HR)","paramValue":"0.72","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA= Median OS, lower limit, and upper limit not reached at time of data cut off","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA= Upper limit not reached at time of data cut off","groupId":"OG001","lowerLimit":"45.7","upperLimit":"NA","value":"52.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"397"},{"groupId":"OG001","value":"400"}],"units":"Participants"}],"description":"OS is defined as the time from randomization until death from any cause. The OS for all participants is presented (through database cut-off date of 10-Jul-2023).","dispersionType":"95% Confidence Interval","groups":[{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, intravenous (IV); given on cycle day 1\\] in combination with platinum doublet neoadjuvant chemotherapy (NAC), consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of pembrolizumab \\[200 mg, IV; given on cycle day 1\\].","id":"OG000","title":"NAC + Neoadjuvant/Adjuvant Pembrolizumab"},{"description":"Neoadjuvant: Prior to surgery, participants receive up to 4 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\] in combination with platinum doublet NAC, consisting of cisplatin \\[75 mg/m\\^2, IV; given on cycle day 1\\] and either Gemcitabine \\[1000 mg/m\\^2, IV; given on cycle days 1 and 8\\] or Pemetrexed \\[500 mg/m\\^2, IV; given on cycle day 1\\].\n\nAdjuvant: 4-12 weeks following surgery, participants receive 13 cycles (cycle length: 3 weeks) of placebo \\[normal saline, IV; given on cycle day 1\\].","id":"OG001","title":"NAC + Neoadjuvant/Adjuvant Placebo"}],"paramType":"MEDIAN","populationDescription":"The analysis population consisted of all randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 5 years","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}